PPD expands Russian presence with Novosibirsk office

Related tags Russia

US CRO PPD has opened a new office in Novosibirsk, Russia to provide clinical monitoring services for its Phase II-IV trial business.

PPD has units in Moscow, Smolensk and St. Petersburg, which in addition to sites it gained with the acquisition of AbCRO in 2009​ and InnoPharm, makes it one of the largest players in Central and Eastern Europe (CEE).

Roger Newbery, PPD’s VP of clinical development in Europe, the Middle East and Africa, said the new office will help “reach more than five million people and grow our number of investigator sites to meet growing client demand.”

News of the Novosibirsk also office follows a week after PPD became a strategic partner for GlaxoSmithKline (GSK) which, given the UK firm’s efforts to target emerging markets, is likely to have factored in the decision to invest.

Related topics Clinical Development Phase III-IV

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Webinars

Headlines